Silo Pharma Secures Japan Patent Allowance for PTSD Treatment Candidate SPC-15

Silo Pharma Inc. (NASDAQ: SILO) announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal therapeutic targeting post-traumatic stress disorder. The application, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," includes composition and method claims and expands Silo's intellectual property portfolio in stress-modulating therapeutics within a key international market. Management noted the allowance supports protection of the Company's core scientific innovations ahead of formal patent grant.

The company's therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Silo Pharma's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's research is conducted in collaboration with leading universities and laboratories, with more information available through their corporate website at https://silopharma.com.

This patent development represents a significant step in protecting Silo Pharma's intellectual property in Japan, a major pharmaceutical market. The allowance comes as the company continues to develop novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The patent application specifically covers methods for preventing stress-induced psychological conditions, which aligns with the growing global focus on mental health treatments and innovative approaches to psychiatric care.

The news follows ongoing developments in the biotechnology sector, where intellectual property protection is crucial for securing investment and advancing clinical research. For investors seeking additional information about Silo Pharma, the latest news and updates relating to SILO are available through specialized financial news platforms that cover the biotechnology and biomedical sectors. These platforms provide access to breaking news and company developments within the life sciences industry.

Patent allowances in key international markets like Japan provide validation for a company's research direction and can facilitate potential partnerships or licensing agreements. For Silo Pharma, this development strengthens their position in the competitive field of stress-modulating therapeutics and supports their broader strategy of addressing unmet medical needs through innovative pharmaceutical approaches. The company's diversified approach includes both traditional biopharmaceutical development and exploration of novel treatment modalities for complex psychiatric conditions.